Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease

Nature Reviews Nephrology

Volumn 10, Issue 12, 2014, Pages 700-711

  Kok, Helena M ^a   Falke, Lucas L ^a   Goldschmeding, Roel ^a   Nguyen, Tri Q ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR DERIVATIVE;

DISEASE COURSE; EXPERIMENTAL MODEL; HUMAN; KIDNEY DISEASE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECTS; FEMALE; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

CONNECTIVE TISSUE GROWTH FACTOR; DISEASE PROGRESSION; EGF FAMILY OF PROTEINS; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84911474274     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.184     Document Type: Review

References (181)

1. Couser, W. G., Remuzzi, G., Mendis, S. & Tonelli, M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 80, 1258-1270 (2011).
2. Schieppati, A. & Remuzzi, G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int. Suppl. 98, S7-S10 (2005).
3. Boor, P., Ostendorf, T. & Floege, J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat. Rev. Nephrol. 6, 643-656 (2010).
4. LeBleu, V. S. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047-1053 (2013).
5. Rüster, C. & Wolf, G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J. Am. Soc. Nephrol. 22, 1189-1199 (2011).
6. Böttinger, E. P. & Bitzer, M. TGF signaling in renal disease. J. Am. Soc. Nephrol. 13, 2600-2610 (2002).
7. Akhurst, R. J. & Hata, A. Targeting the TGF signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790-811 (2012).
8. Perbal, B. CCN proteins: multifunctional signalling regulators. Lancet 363, 62-64 (2004).
9. Falke, L. L., Goldschmeding, R. & Nguyen, T. Q. A perspective on anti-CCN2 therapy for chronic kidney disease. Nephrol. Dial. Transplant. 29 (Suppl. 1), i30-i37 (2014).
10. Grotendorst, G. R., Okochi, H. & Hayashi, N. A novel transforming growth factor - response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ. 7, 469-480 (1996).
11. Ito, Y. et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 53, 853-861 (1998).
12. Sánchez-López, E. et al. CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NFB. J. Am. Soc. Nephrol. 20, 1513-1526 (2009).
13. Liu, S. C., Hsu, C. J., Fong, Y. C., Chuang, S. M. & Tang, C. H. CTGF induces monocyte chemoattractant protein-1 expression to enhance monocyte migration in human synovial fibroblasts. Biochim. Biophys. Acta 1833, 1114-1124 (2013).
14. Wang, Q. et al. Cooperative interaction of CTGF and TGF in animal models of fibrotic disease. Fibrogenesis Tissue Repair 4, 4 (2011).
15. Yokoi, H. et al. Role of connective tissue growth factor in profibrotic action of transforming growth factor: a potential target for preventing renal fibrosis. Am. J. Kidney Dis. 38, S134-S138 (2001).
16. Abreu, J. G., Ketpura, N. I., Reversade, B. & De Robertis, E. M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF?. Nat. Cell Biol. 4, 599-604 (2002).
17. Wahab, N. A., Weston, B. S. & Mason, R. M. Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J. Am. Soc. Nephrol. 16, 340-351 (2005).
18. Rayego-Mateos, S. et al. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. J. Mol. Cell Biol. 5, 323-335 (2013).
19. Cheng, X. et al. Both ERK/MAPK and TGF-/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation. J. Diabetes Res. 2013, 463740 (2013).
20. Mason, R. M. Fell-Muir lecture: Connective tissue growth factor (CCN2) - A pernicious and pleiotropic player in the development of kidney fibrosis. Int. J. Exp. Pathol. 94, 1-16 (2013).
21. Rooney, B. et al. CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett. 585, 531-538 (2011).
22. Lau, L. F. & Lam, S. C. The CCN family of angiogenic regulators: the integrin connection. Exp. Cell Res. 248, 44-57 (1999).
23. Nguyen, T. Q. et al. CTGF inhibits BMP7 signaling in diabetic nephropathy. J. Am. Soc. Nephrol. 19, 2098-2107 (2008).
24. Boon, M. R. et al. Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev. 22, 221-229 (2011).
25. Cheng, O. et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am. J. Transplant. 6, 2292-2306 (2006).
26. Kanemoto, K. et al. Connective tissue growth factor participates in scar formation of crescentic glomerulonephritis. Lab. Invest. 83, 1615-1625 (2003).
27. Ito, Y. et al. Involvement of connective tissue growth factor in human and experimental hypertensive nephrosclerosis. Nephron Exp. Nephrol. 117, e9-e20 (2011).
28. Nguyen, T. Q. et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 31, 1177-1182 (2008).
29. Gerritsen, K. G. et al. Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion. Am. J. Physiol. Renal Physiol. 298, F1457-F1464 (2010).
30. Gerritsen, K. G. et al. Effect of GFR on plasma N-terminal connective tissue growth factor (CTGF) concentrations. Am. J. Kidney Dis. 59, 619-627 (2012).
31. Nguyen, T. Q. et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 29, 83-88 (2006).
32. Riser, B. L. et al. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int. 64, 451-458 (2003).
33. Tam, F. W. et al. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 47, 37-42 (2009).
34. Metalidis, C. et al. Urinary connective tissue growth factor is associated with human renal allograft fibrogenesis. Transplantation 96, 494-500 (2013).
35. Dendooven, A., Gerritsen, K. G., Nguyen, T. Q., Kok, R. J. & Goldschmeding, R. Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 16, 289-301 (2011).
36. Wang, B. et al. Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. J. Med. Genet. 47, 391-397 (2010).
37. Fonseca, C. et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N. Engl. J. Med. 357, 1210-1220 (2007).
38. Dendooven, A. et al. The CTGF-945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. J. Negat. Results Biomed. 10, 4 (2011).
39. Patel, S. K. et al. The CTGF gene-945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes. Cardiovasc. Diabetol. 11, 42 (2012).
40. Ivkovic, S. et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130, 2779-2791 (2003).
41. Baguma-Nibasheka, M. & Kablar, B. Pulmonary hypoplasia in the connective tissue growth factor (Ctgf) null mouse. Dev. Dyn. 237, 485-493 (2008).
42. Yokoi, H. et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 15, 1430-1440 (2004).
43. Luo, G. H. et al. Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant. Proc. 40, 2365-2369 (2008).
44. Guha, M., Xu, Z. G., Tung, D., Lanting, L. & Natarajan, R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 21, 3355-3368 (2007).
45. Falke, L. L. et al. Hemizygous deletion of CTGF/CCN2 does not suffice to prevent fibrosis of the severely injured kidney. Matrix Biol. 31, 421-431 (2012).
46. Yokoi, H. et al. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int. 73, 446-455 (2008).
47. Fragiadaki, M. et al. Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo. Matrix Biol. 30, 396-403 (2011).
48. Adler, S. G. et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol. 5, 1420-1428 (2010).
49. Riser, B. L. et al. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am. J. Pathol. 174, 1725-1734 (2009).
50. van Roeyen, C. R. et al. A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and antimesangioproliferative effects. Am. J. Pathol. 180, 1979-1990 (2012).
51. Morales, M. G. et al. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy. Hum. Mol. Genet. 22, 4938-4951 (2013).
52. Wang, X. et al. A novel single-chain-Fv antibody against connective tissue growth factor attenuates bleomycin-induced pulmonary fibrosis in mice. Respirology 16, 500-507 (2011).
53. Lipson, K. E., Wong, C., Teng, Y. & Spong, S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 5 (Suppl. 1), S24 (2012).
54. Aikawa, T., Gunn, J., Spong, S. M., Klaus, S. J. & Korc, M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol. Cancer Ther. 5, 1108-1116 (2006).
55. Finger, E. C. et al. CTGF is a therapeutic target for metastatic melanoma. Oncogene 33, 1093-1100 (2014).
56. Neesse, A. et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc. Natl Acad. Sci. USA 110, 12325-12330 (2013).
57. Yoon, P. O. et al. The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. J. Mol. Cell. Cardiol. 49, 294-303 (2010).
58. Panek, A. N. et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS ONE 4, e6743 (2009).
59. Ahmed, M. S. et al. Mechanisms of novel cardioprotective functions of CCN2/CTGF in myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 300, H1291-H1302 (2011).
60. Gravning, J. et al. Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction. PLoS ONE 7, e52120 (2012).
61. Leeuwis, J. W. et al. Connective tissue growth factor is associated with a stable atherosclerotic plaque phenotype and is involved in plaque stabilization after stroke. Stroke 41, 2979-2981 (2010).
62. Schlessinger, J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110, 669-672 (2002).
63. Holbro, T. & Hynes, N. E. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 44, 195-217 (2004).
64. Miettinen, P. J. et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376, 337-341 (1995).
65. Sibilia, M. & Wagner, E. F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269, 234-238 (1995).
66. Threadgill, D. W. et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269, 230-234 (1995).
67. Chen, J., Chen, J. K. & Harris, R. C. Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury. Kidney Int. 82, 45-52 (2012).
68. Kennedy, W. A. 2nd et al. Epidermal growth factor suppresses renal tubular apoptosis following ureteral obstruction. Urology 49, 973-980 (1997).
69. Huovila, A. P., Turner, A. J., Pelto-Huikko, M., Kärkkäinen, I. & Ortiz, R. M. Shedding light on ADAM metalloproteinases. Trends Biochem. Sci. 30, 413-422 (2005).
70. Bollée, G. et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat. Med. 17, 1242-1250 (2011).
71. Laouari, D. et al. TGF mediates genetic susceptibility to chronic kidney disease. J. Am. Soc. Nephrol. 22, 327-335 (2011).
72. Lautrette, A. et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat. Med. 11, 867-874 (2005).
73. Shah, B. H. & Catt, K. J. TACE-dependent EGF receptor activation in angiotensin-II-induced kidney disease. Trends Pharmacol. Sci. 27, 235-237 (2006).
74. Melenhorst, W. B. et al. Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. Hypertension 52, 987-993 (2008).
75. Yoshioka, K. et al. Identification and localization of epidermal growth factor and its receptor in the human glomerulus. Lab. Invest. 63, 189-196 (1990).
76. Tang, J., Liu, N. & Zhuang, S. Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int. 83, 804-810 (2013).
77. Jørgensen, P. E. et al. Renal uptake and excretion of epidermal growth factor from plasma in the rat. Regul. Pept. 28, 273-281 (1990).
78. Kwon, O. et al. Simultaneous monitoring of multiple urinary cytokines may predict renal and patient outcome in ischemic AKI. Ren. Fail. 32, 699-708 (2010).
79. Ranieri, E., Gesualdo, L., Petrarulo, F. & Schena, F. P. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int. 50, 1990-2001 (1996).
80. Stangou, M. et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology (Carlton) 14, 613-620 (2009).
81. Grandaliano, G. et al. MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney Int. 58, 182-192 (2000).
82. Tsau, Y. & Chen, C. Urinary epidermal growth factor excretion in children with chronic renal failure. Am. J. Nephrol. 19, 400-404 (1999).
83. Nakopoulou, L. et al. Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury. Nephrol. Dial. Transplant. 9, 764-769 (1994).
84. Sis, B. et al. Epidermal growth factor receptor expression in human renal allograft biopsies: an immunohistochemical study. Transpl. Immunol. 13, 229-232 (2004).
85. Gilbert, R. E. et al. Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia 40, 778-785 (1997).
86. Guh, J. Y., Lai, Y. H., Shin, S. J., Chuang, L. Y. & Tsai, J. H. Epidermal growth factor in renal hypertrophy in streptozotocin-diabetic rats. Nephron 59, 641-647 (1991).
87. Torres, V. E. et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int. 64, 1573-1579 (2003).
88. Benter, I. F., Canatan, H., Benboubetra, M., Yousif, M. H. & Akhtar, S. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. Vascul. Pharmacol. 51, 101-109 (2009).
89. Advani, A. et al. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology (Carlton) 16, 573-581 (2011).
90. Paizis, K. et al. Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis. Kidney Int. 55, 2310-2321 (1999).
91. Mishra, R., Leahy, P. & Simonson, M. S. Gene expression profiling reveals role for EGF-family ligands in mesangial cell proliferation. Am. J. Physiol. Renal Physiol. 283, F1151-F1159 (2002).
92. Nemo, R., Murcia, N. & Dell, K. M. Transforming growth factor - (TGF) and other targets of tumor necrosis factor converting enzyme (TACE) in murine polycystic kidney disease. Pediatr. Res. 57, 732-737 (2005).
93. Waheed, S. et al. Transforming growth factor (TGF) is increased during hyperoxia and fibrosis. Exp. Lung Res. 28, 361-372 (2002).
94. Terzi, F. et al. Targeted expression of a dominant-negative EGFR in the kidney reduces tubulo-interstitial lesions after renal injury. J. Clin. Invest. 106, 225-234 (2000).
95. Chen, J. et al. EGFR signaling promotes TGF-dependent renal fibrosis. J. Am. Soc. Nephrol. 23, 215-224 (2012).
96. Luetteke, N. C. et al. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 8, 399-413 (1994).
97. Richards, W. G. et al. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J. Clin. Invest. 101, 935-939 (1998).
98. Liu, N. et al. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J. Am. Soc. Nephrol. 23, 854-867 (2012).
99. Tang, J. et al. Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am. J. Pathol. 183, 160-172 (2013).
100. Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H. & Rigas, J. R. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat. Rev. 39, 839-850 (2013).
101. Hoekstra, R. et al. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. 11, 6908-6915 (2005).
102. François, H. et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J. 18, 926-928 (2004).
103. Wassef, L., Kelly, D. J. & Gilbert, R. E. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int. 66, 1805-1814 (2004).
104. Bou Matar, R. N., Klein, J. D. & Sands, J. M. Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats. PLoS ONE 8, e54738 (2013).
105. He, S., Liu, N., Bayliss, G. & Zhuang, S. EGFR activity is required for renal tubular cell dedifferentiation and proliferation in a murine model of folic acid-induced acute kidney injury. Am. J. Physiol. Renal Physiol. 304, F356-F366 (2013).
106. Wang, Z., Chen, J. K., Wang, S. W., Moeckel, G. & Harris, R. C. Importance of functional EGF receptors in recovery from acute nephrotoxic injury. J. Am. Soc. Nephrol. 14, 3147-3154 (2003).
107. Mulder, G. M. et al. Heparin binding epidermal growth factor in renal ischaemia/reperfusion injury. J. Pathol. 221, 183-192 (2010).
108. Samarakoon, R. et al. Induction of renal fibrotic genes by TGF-1 requires EGFR activation, p53 and reactive oxygen species. Cell. Signal. 25, 2198-2209 (2013).
109. Masutani, K. et al. Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. Clin. Exp. Nephrol. 12, 398-402 (2008).
110. Banappagari, S., Corti, M., Pincus, S. & Satyanarayanajois, S. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic. J. Biomol. Struct. Dyn. 30, 594-606 (2012).
111. Vlacich, G. & Coffey, R. J. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell 20, 423-425 (2011).
112. Ross, R., Glomset, J., Kariya, B. & Harker, L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc. Natl Acad. Sci. USA 71, 1207-1210 (1974).
113. Fredriksson, L., Li, H. & Eriksson, U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 15, 197-204 (2004).
114. Alpers, C. E., Seifert, R. A., Hudkins, K. L., Johnson, R. J. & Bowen-Pope, D. F. Developmental patterns of PDGF B-chain, PDGF-receptor, and actin expression in human glomerulogenesis. Kidney Int. 42, 390-399 (1992).
115. Boor, P., Ostendorf, T. & Floege, J. PDGF and the progression of renal disease. Nephrol. Dial. Transplant. 29 (Suppl. 1), i45-i54 (2014).
116. Alpers, C. E., Seifert, R. A., Hudkins, K. L., Johnson, R. J. & Bowen-Pope, D. F. PDGF-receptor localizes to mesangial, parietal epithelial, and interstitial cells in human and primate kidneys. Kidney Int. 43, 286-294 (1993).
117. Floege, J., Eitner, F. & Alpers, C. E. A new look at platelet-derived growth factor in renal disease. J. Am. Soc. Nephrol. 19, 12-23 (2008).
118. Alpers, C. E., Hudkins, K. L., Ferguson, M., Johnson, R. J. & Rutledge, J. C. Platelet-derived growth factor A-chain expression in developing and mature human kidneys and in Wilms' tumor. Kidney Int. 48, 146-154 (1995).
119. Boström, H. et al. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85, 863-873 (1996).
120. Levéen, P. et al. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 8, 1875-1887 (1994).
121. Lindahl, P., Johansson, B. R., Levéen, P. & Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242-245 (1997).
122. Chen, Y. T. et al. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int. 80, 1170-1181 (2011).
123. Chen, P. H., Chen, X. & He, X. Platelet-derived growth factors and their receptors: structural and functional perspectives. Biochim. Biophys. Acta 1834, 2176-2186 (2013).
124. Reigstad, L. J., Varhaug, J. E. & Lillehaug, J. R. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J. 272, 5723-5741 (2005).
125. Wang, S. N. & Hirschberg, R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am. J. Physiol. Renal Physiol. 278, F554-F560 (2000).
126. Liu, Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am. J. Physiol. Renal Physiol. 287, F7-F16 (2004).
127. Hudkins, K. L. et al. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J. Am. Soc. Nephrol. 15, 286-298 (2004).
128. Floege, J., van Roeyen, C., Boor, P. & Ostendorf, T. The role of PDGF-D in mesangioproliferative glomerulonephritis. Contrib. Nephrol. 157, 153-158 (2007).
129. van Roeyen, C. R. et al. Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D. Kidney Int. 80, 1292-1305 (2011).
130. Iida, H. et al. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc. Natl Acad. Sci. USA 88, 6560-6564 (1991).
131. Matsuda, M. et al. Gene expression of PDGF and PDGF receptor in various forms of glomerulonephritis. Am. J. Nephrol. 17, 25-31 (1997).
132. Waldherr, R. et al. Expression of cytokines and growth factors in human glomerulonephritides. Pediatr. Nephrol. 7, 471-478 (1993).
133. Gesualdo, L. et al. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J. Clin. Invest. 94, 50-58 (1994).
134. Eitner, F. et al. PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J. Am. Soc. Nephrol. 14, 1145-1153 (2003).
135. Liu, G. et al. Identification of platelet-derived growth factor D in human chronic allograft nephropathy. Hum. Pathol. 39, 393-402 (2008).
136. Taneda, S. et al. Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J. Am. Soc. Nephrol. 14, 2544-2555 (2003).
137. Boor, P. et al. Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. Nephrol. Dial. Transplant. 24, 2755-2762 (2009).
138. Har, R. et al. The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia 56, 1166-1173 (2013).
139. Nakamura, H. et al. Electroporation-mediated PDGF receptor-IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney Int. 59, 2134-2145 (2001).
140. Ostendorf, T. et al. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J. Am. Soc. Nephrol. 14, 2237-2247 (2003).
141. Boor, P. et al. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol. Dial. Transplant. 22, 1323-1331 (2007).
142. Ostendorf, T. et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 12, 909-918 (2001).
143. Ostendorf, T. et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 17, 1054-1062 (2006).
144. Suzuki, H. et al. Deletion of platelet-derived growth factor receptor improves diabetic nephropathy in Ca2+/calmodulin-dependent protein kinase II (Thr286Asp) transgenic mice. Diabetologia 54, 2953-2962 (2011).
145. Ludewig, D., Kosmehl, H., Sommer, M., Böhmer, F. D. & Stein, G. PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res. 299, 97-103 (2000).
146. Boor, P. et al. PDGF-C mediates glomerular capillary repair. Am. J. Pathol. 177, 58-69 (2010).
147. Eitner, F. et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J. Am. Soc. Nephrol. 19, 281-289 (2008).
148. Martin, I. V. et al. Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. Am. J. Pathol. 182, 107-117 (2013).
149. Iyoda, M., Shibata, T., Kawaguchi, M., Yamaoka, T. & Akizawa, T. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney Int. 75, 1060-1070 (2009).
150. Iyoda, M. et al. Long-and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis. Nephrol. Dial. Transplant. 28, 576-584 (2013).
151. Sadanaga, A. et al. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum. 52, 3987-3996 (2005).
152. Zoja, C. et al. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 70, 97-103 (2006).
153. Iyoda, M. et al. Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. J. Am. Soc. Nephrol. 20, 68-77 (2009).
154. Lassila, M. et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J. Am. Soc. Nephrol. 16, 363-373 (2005).
155. Graciano, M. L. & Mitchell, K. D. Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am. J. Physiol. Renal Physiol. 302, F60-F69 (2012).
156. Schellings, M. W. et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 47, 467-474 (2006).
157. Savikko, J., Taskinen, E. & Von Willebrand, E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 75, 1147-1153 (2003).
158. Wang, S., Wilkes, M. C., Leof, E. B. & Hirschberg, R. Imatinib mesylate blocks a non-Smad TGF pathway and reduces renal fibrogenesis in vivo. FASEB J. 19, 1-11 (2005).
159. Avlan, D. et al. Effects of trapidil on renal ischemia-reperfusion injury. J. Pediatr. Surg. 41, 1686-1693 (2006).
160. Büyükafşar, K. et al. Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats. Pharmacol. Res. 44, 321-328 (2001).
161. Futamura, A. et al. Effect of the platelet-derived growth factor antagonist trapidil on mesangial cell proliferation in rats. Nephron 81, 428-433 (1999).
162. Razzaque, M. S., Cheng, M. & Taguchi, T. Suppression of mesangial-cell proliferation by trapidil in glomerulonephritis induced by anti-thymocyte serum in rats. J. Int. Med. Res. 23, 458-466 (1995).
163. Shinkai, Y. & Cameron, J. S. Trial of platelet-derived growth factor antagonist, trapidil, in accelerated nephrotoxic nephritis in the rabbit. Br. J. Exp. Pathol. 68, 847-852 (1987).
164. Nakagawa, T. et al. Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury. Am. J. Pathol. 155, 1689-1699 (1999).
165. Chen, J., Chen, J. K., Neilson, E. G. & Harris, R. C. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J. Am. Soc. Nephrol. 17, 1615-1623 (2006).
166. Urtasun, R. et al. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 54, 2149-2158 (2011).
167. Andrianifahanana, M. et al. Profibrotic TGF responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. FASEB J. 27, 4444-4454 (2013).
168. Nguyen, T. Q. & Goldschmeding, R. Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? Pharm. Res. 25, 2416-2426 (2008).
169. Sweeney, W. E., Chen, Y., Nakanishi, K., Frost, P. & Avner, E. D. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 57, 33-40 (2000).
170. Hirai, T., Masaki, T., Kuratsune, M., Yorioka, N. & Kohno, N. PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation. Clin. Exp. Immunol. 144, 353-361 (2006).
171. Wang-Rosenke, Y. et al. Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat. BMC Nephrol. 14, 223 (2013).
172. Johnson, R. J. et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J. Exp. Med. 175, 1413-1416 (1992).
173. Takahashi, T. et al. Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis. J. Biol. Chem. 280, 7100-7106 (2005).
174. Floege, J. et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol. 154, 169-179 (1999).
175. Kishioka, H. et al. Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats. Am. J. Hypertens. 14, 439-445 (2001).
176. Gravning, J., Ahmed, M. S., von Lueder, T. G., Edvardsen, T. & Attramadal, H. CCN2/CTGF attenuates myocardial hypertrophy and cardiac dysfunction upon chronic pressure-overload. Int. J. Cardiol. 168, 2049-2056 (2013).
177. Quan, T., Shao, Y., He, T., Voorhees, J. J. & Fisher, G. J. Reduced expression of connective tissue growth factor (CTGF/CCN2) mediates collagen loss in chronologically aged human skin. J. Invest. Dermatol. 130, 415-424 (2010).
178. Pastore, S., Lulli, D. & Girolomoni, G. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch. Toxicol. 88, 1189-1203 (2014).
179. Hartmann, J. T., Haap, M., Kopp, H. G. & Lipp, H. P. Tyrosine kinase inhibitors - A review on pharmacology, metabolism and side effects. Curr. Drug Metab. 10, 470-481 (2009).
180. Fallahi, P. et al. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin. Drug Saf. 13, 723-733 (2014).
181. Korashy, H. M., Rahman, A. F. & Kassem, M. G. Dasatinib. Profiles Drug Subst. Excip. Relat. Methodol. 39, 205-237 (2014).